{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:37Z","timestamp":1787010157990,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010804","name":"Faculty of Medicine, Prince of Songkla University","doi-asserted-by":"crossref","award":["REC 60-069-02-1"],"award-info":[{"award-number":["REC 60-069-02-1"]}],"id":[{"id":"10.13039\/501100010804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with ocular myasthenia gravis (OMG) are frequently treated to prevent the development of generalized myasthenia gravis (GMG). This retrospective cohort study aimed to assess prognostic factors associated with conversion to GMG.<\/jats:p>\n                    <jats:p>We analyzed the time from the onset of OMG symptoms to GMG in relation to demographic variables, clinical findings, initial investigation results, and treatment regimens using Kaplan\u2013Meier survival curves and multivariate Cox proportional regression analysis.<\/jats:p>\n                    <jats:p>\n                      Of 115 patients diagnosed with OMG (median follow-up time, 2.9\u200ayears), 28 (30.4%) developed GMG. The 2-year probability of GMG conversion was 23.7%. Patients with thymic abnormalities and a positive response to repetitive facial nerve stimulation had a significantly higher risk than those with negative results (hazard ratios [HR] 4.28,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001 and HR 3.84,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.04, respectively). Treatment with immunosuppressants was found to be a preventive factor for secondary generalization (HR 0.36,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.02).\n                    <\/jats:p>\n                    <jats:p>Patients with OMG had a low risk of developing GMG. Immunosuppressive treatments may mitigate disease progression. Chest imaging and repetitive nerve stimulation should be routinely performed to assess the risk of generalization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000025899","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T15:59:06Z","timestamp":1620748746000},"page":"e25899","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Prognostic factors for conversion to generalization in ocular myasthenia gravis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-6384","authenticated-orcid":false,"given":"Juthamat","family":"Witthayaweerasak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narisa","family":"Rattanalert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipat","family":"Aui-aree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","article-title":"Ocular myasthenia gravis: controversies and updates","volume":"14","author":"Wong","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of ocular myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann Neurol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0b013e328310da18","article-title":"Medical treatment options for ocular myasthenia gravis","volume":"19","author":"Antonio-Santos","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"R6-20250504","first-page":"Cd005081","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"12","author":"Benatar","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of corticosteroids on ocular myasthenia gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch Neurol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J Neuroophthalmol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2\u200ayears in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch Neurol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J Neurol Sci"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long-term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","article-title":"Ocular myasthenia gravis: Toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification","volume":"36","author":"Wong","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.25971","article-title":"Ocular presentation of myasthenia gravis: a natural history cohort","volume":"57","author":"Kamarajah","year":"2018","journal-title":"Muscle Nerve"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/mus.25983","article-title":"Low conversion rate of ocular to generalized myasthenia gravis in Singapore","volume":"57","author":"Teo","year":"2018","journal-title":"Muscle Nerve"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","article-title":"Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody","volume":"209","author":"Apinyawasisuk","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia","year":"2015","journal-title":"Ophthalmology"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000487132","article-title":"Prognosis of ocular myasthenia gravis in an Argentinian population","volume":"79","author":"Aguirre","year":"2018","journal-title":"Eur Neurol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000324915","article-title":"Repetitive nerve stimulation of facial and hypothenar muscles: relative sensitivity in different myasthenia gravis subgroups","volume":"65","author":"Zambelis","year":"2011","journal-title":"Eur Neurol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mus.10411","article-title":"Decremental response of the nasalis and hypothenar muscles in myasthenia gravis","volume":"28","author":"Niks","year":"2003","journal-title":"Muscle Nerve"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.clinph.2004.05.024","article-title":"Repetitive nerve stimulation in myasthenia gravis - relative sensitivity of different muscles","volume":"115","author":"Costa","year":"2004","journal-title":"Clin Neurophysiol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/01.cnd.0000155026.66153.f0","article-title":"A comparison of electrodiagnostic tests in ocular myasthenia gravis","volume":"6","author":"Katzberg","year":"2005","journal-title":"J Clin Neuromuscul Dis"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S0161-6420(99)00709-5","article-title":"An ice test for the diagnosis of myasthenia gravis","volume":"106","author":"Golnik","year":"1999","journal-title":"Ophthalmology"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.ophtha.2009.04.039","article-title":"The ice pack test in the differential diagnosis of myasthenic diplopia","volume":"116","author":"Chatzistefanou","year":"2009","journal-title":"Ophthalmology"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","article-title":"Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response","volume":"13","author":"Mittal","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","article-title":"SFEMG in ocular myasthenia gravis diagnosis","volume":"111","author":"Padua","year":"2000","journal-title":"Clin Neurophysiol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/mus.21555","article-title":"Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis","volume":"41","author":"Allen","year":"2010","journal-title":"Muscle Nerve"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12883-020-01805-1","article-title":"Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Neurol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:42:56Z","timestamp":1746322976000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":35,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025899","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"2021-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}